Your browser doesn't support javascript.
loading
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag, P; Gutzmer, R; Ascierto, P A; Maio, M; Grob, J-J; Murawa, P; Dreno, B; Ross, M; Weber, J; Hauschild, A; Rutkowski, P; Testori, A; Levchenko, E; Enk, A; Misery, L; Vanden Abeele, C; Vojtek, I; Peeters, O; Brichard, V G; Therasse, P.
Afiliação
  • Saiag P; General Dermatology and Oncology Service, Ambroise-Paré Hospital, AP-HP, University of Versailles-Saint-Quentin-en-Yvelines, Boulogne, France philippe.saiag@uvsq.fr.
  • Gutzmer R; Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
  • Ascierto PA; National Institute for Tumors Foundation 'G. Pascale', Napoli.
  • Maio M; Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
  • Grob JJ; Department of Dermatology and Skin Cancers, La Timone APHM Hospital, Aix-Marseille University, Marseille, France.
  • Murawa P; Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland.
  • Dreno B; Dermatology Clinic, Hôtel-Dieu Hospital, CHU Nantes, Nantes, France.
  • Ross M; Department of Surgical Oncology, UTMD Anderson Cancer Center, Houston.
  • Weber J; Moffitt Cancer Center, Tampa, USA.
  • Hauschild A; Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Center and Institute of Oncology, Warsaw, Poland.
  • Testori A; Melanoma and Soft Tissue Sarcoma Division, European Institute of Oncology, Milan, Italy.
  • Levchenko E; Petrov Research Institute of Oncology, St Petersburg, Russian Federation.
  • Enk A; Department of Dermatology, University of Heidelberg, Heidelberg, Germany.
  • Misery L; Department of Dermatology, University Hospital of Brest, Brest, France.
  • Vanden Abeele C; GSK Vaccines, Rixensart, Belgium.
  • Vojtek I; GSK Vaccines, Rixensart, Belgium.
  • Peeters O; GSK Vaccines, Rixensart, Belgium.
  • Brichard VG; GSK Vaccines, Rixensart, Belgium.
  • Therasse P; GSK Vaccines, Rixensart, Belgium.
Ann Oncol ; 27(10): 1947-53, 2016 10.
Article em En | MEDLINE | ID: mdl-27502712
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma / Antígenos de Neoplasias / Proteínas de Neoplasias Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma / Antígenos de Neoplasias / Proteínas de Neoplasias Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido